Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Esophageal Clinical Trial

Official title:
The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Status Completed

Clinical Trial Summary

Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours.

Clinical Trial Description

Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02591784
Study type	Interventional
Source	Biotech Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	November 2008
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01842555` - Photodynamic Therapy (PDT) Oncology Registry
Terminated	`NCT00618917` - MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)	Phase 1/Phase 2
Completed	`NCT02374255` - Improving Goals of Care Discussion in Advanced Cancer Patients	N/A
Terminated	`NCT01365130` - Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen	Phase 2
Terminated	`NCT02749526` - Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial	Phase 2